195 related articles for article (PubMed ID: 37286146)
21. Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.
Reyes HD; Thiel KW; Carlson MJ; Meng X; Yang S; Stephan JM; Leslie KK
Mol Diagn Ther; 2014 Apr; 18(2):137-51. PubMed ID: 24403167
[TBL] [Abstract][Full Text] [Related]
22. Taxanes: their impact on gynecologic malignancy.
Schwab CL; English DP; Roque DM; Santin AD
Anticancer Drugs; 2014 May; 25(5):522-35. PubMed ID: 24300913
[TBL] [Abstract][Full Text] [Related]
23. Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.
Wolford JE; Ferrigni E; Margul D; Herzog TJ
Curr Oncol Rep; 2022 Jul; 24(7):889-904. PubMed ID: 35347591
[TBL] [Abstract][Full Text] [Related]
24. Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets.
Rasila KK; Burger RA; Smith H; Lee FC; Verschraegen C
Int J Gynecol Cancer; 2005; 15(5):710-26. PubMed ID: 16174217
[TBL] [Abstract][Full Text] [Related]
25. An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group.
Shimada M; Yoshihara K; Tanigawa T; Nomura H; Hamanishi J; Fujiwara S; Tanabe H; Kajiyama H; Mandai M; Aoki D; Enomoto T; Okamoto A
J Gynecol Oncol; 2023 May; 34(3):e62. PubMed ID: 37116954
[TBL] [Abstract][Full Text] [Related]
26. Exploring Phytochemicals from Himalayan Medicinal Plants as Novel Therapeutic Agents.
Saini N; Lather V; Gahlawat SK
Anticancer Agents Med Chem; 2022; 22(9):1674-1698. PubMed ID: 34773963
[TBL] [Abstract][Full Text] [Related]
27. Metastatic gynecologic malignancies: advances in treatment and management.
Chan JK; Chow S; Bhowmik S; Mann A; Kapp DS; Coleman RL
Clin Exp Metastasis; 2018 Aug; 35(5-6):521-533. PubMed ID: 29931499
[TBL] [Abstract][Full Text] [Related]
28. LHRH agonist treatment of breast cancer and gynecological malignancies: a review.
Burger CW; Prinssen HM; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 1996 Jul; 67(1):27-33. PubMed ID: 8789746
[TBL] [Abstract][Full Text] [Related]
29. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
Tolcher A; Hamilton E; Coleman RL
Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
[TBL] [Abstract][Full Text] [Related]
30. Anti-angiogenesis therapy in gynecologic malignancies.
Liu FW; Cripe J; Tewari KS
Oncology (Williston Park); 2015 May; 29(5):350-60. PubMed ID: 25979545
[TBL] [Abstract][Full Text] [Related]
31. Roles of plant-derived bioactive compounds and related microRNAs in cancer therapy.
Zou H; Li Y; Liu X; Wu Z; Li J; Ma Z
Phytother Res; 2021 Mar; 35(3):1176-1186. PubMed ID: 33000538
[TBL] [Abstract][Full Text] [Related]
32. Insights on the anticancer potential of plant-food bioactives: A key focus to prostate cancer.
Salehi B; Tsouh Fokou PV; Yamthe LRT; Tali BT; Adetunji CO; Rahavian A; Mudau FN; Martins N; Martorell M; Rodrigues CF; Setzer WN; Sharifi-Rad M; Amarowicz R; Sharifi-Rad J
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(4):250-263. PubMed ID: 32583798
[TBL] [Abstract][Full Text] [Related]
33. CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies.
Sun C; Duan P; Luan C
Curr Drug Targets; 2017; 18(10):1142-1151. PubMed ID: 28031014
[TBL] [Abstract][Full Text] [Related]
34. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
35. Circadian chemotherapy for gynecological and genitourinary cancers.
Kobayashi M; Wood PA; Hrushesky WJ
Chronobiol Int; 2002 Jan; 19(1):237-51. PubMed ID: 11962679
[TBL] [Abstract][Full Text] [Related]
36. Potential phytochemicals in the prevention and treatment of esophagus cancer: A green therapeutic approach.
Abbasi BA; Iqbal J; Ahmad R; Bibi S; Mahmood T; Kanwal S; Bashir S; Gul F; Hameed S
Pharmacol Rep; 2019 Aug; 71(4):644-652. PubMed ID: 31181380
[TBL] [Abstract][Full Text] [Related]
37. COX-2-PGE
Ye Y; Wang X; Jeschke U; von Schönfeldt V
Arch Gynecol Obstet; 2020 Jun; 301(6):1365-1375. PubMed ID: 32363546
[TBL] [Abstract][Full Text] [Related]
38. Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.
Vaidya AP; Parnes AD; Seiden MV
Curr Treat Options Oncol; 2005 Mar; 6(2):103-14. PubMed ID: 15717992
[TBL] [Abstract][Full Text] [Related]
39. The gut microbiome and cancer immunotherapeutics: A review of emerging data and implications for future gynecologic cancer research.
McKenzie ND; Hong H; Ahmad S; Holloway RW
Crit Rev Oncol Hematol; 2021 Jan; 157():103165. PubMed ID: 33227575
[TBL] [Abstract][Full Text] [Related]
40. Roles of Medicinal Plants and Constituents in Gynecological Cancer Therapy: Current Literature and Future Directions.
Akkol EK; Dereli FTG; Sobarzo-Sánchez E; Khan H
Curr Top Med Chem; 2020; 20(20):1772-1790. PubMed ID: 32297581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
